Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-609-3 | CAS number: 65-45-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
13-week oral-gavage study, rat, highest dose 200 mg/kg bw, no guideline, Ichniowski 1946. No signs of toxicity or histopathological changes. Leucopenia suspected, but not reproducible in second, specific hematology study.
67-day drinking water study, mouse, 250mg/kg, no guideline, Drebinger 1952. No signs of toxicity
Combined 3-generation study, mouse, no guideline, non-standard method, Wright 1967. Depression of physical condition, shortening of survival time, no increase in mammary carcinoma.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study published in a peer-reviewed journal. Performed before GLP and OECD guidelines were introduced. Experimental details documented, but no data on housing, no individual animal records (body weight, food consumption, mortality, etc.). Maximum dose (200 mg/kg bw) too low for limit test. Sufficient numbers of animals (10 M, 10 F per dose), hematology and histology performed, but not reported in detail. Death rates similar in all dose groups, all deaths attributed to faulty (intratracheal) administration, on the basis of necropsy findings.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Gavage application 13 weeks, 5 times/week, post mortem examination, hematology and histopathology in some animals, recovery time 3-7 weeks in some animals. No control group; application only five days per week; no data on acclimatization and housing; only summary data on weight development, rudimentary clinical laboratory data; high losses due to intratracheal application.
- GLP compliance:
- no
- Remarks:
- GLP not available at study time
- Limit test:
- no
- Species:
- rat
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: no data
- Weight at study initiation: 100 - 130 g
- Fasting period before study: no
- Housing, diet, water, acclimation period: no data
ENVIRONMENTAL CONDITIONS
- no data - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% gum tragacanth in water
- Details on oral exposure:
- VEHICLE
- Justification for use and choice of vehicle (if other than water): stability of test substance, tolerability of vehicle (confounding effect of alcohols)
- Concentration in vehicle: depending on dose
- Amount of vehicle (if gavage): 10 or 20 ml/kg bw - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 5 times per week, totally 67 doses
- Remarks:
- Doses / Concentrations:
5, 25, 50, 100, and 200 mg/kg bw
Basis:
other: applied by gavage - No. of animals per sex per dose:
- 10 males, 10 females
- Control animals:
- no
- Details on study design:
- - Dose selection rationale: 1, 5, 10, 20, and 40 times average human adult dose
- Rationale for animal assignment (if not random): no data
- Rationale for selecting satellite groups: Some animals sacrificed at end of treatment, for hematologic studies; others injected with 4% formaldehyde for histologic examination, 3 - 7 weeks after cessation of treatment
- Post-exposure recovery period in satellite groups: 3 - 7 weeks
- Section schedule rationale (if not random): no data - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes, but no results reported
- Time schedule: no data
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes, but only summary findings reported
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption: No data
- Compound intake: total: 70 mg - 13400 mg / animal, calculated from gavage amounts
FOOD EFFICIENCY:
- No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: sacrifice at end of treatment
- Anaesthetic used for blood collection: No
- Animals fasted: No data
- How many animals: 19 (allocation to dose groups not stated)
- Parameters checked: prothrombin time, coagulation time, hemoglobin, erythrocyte count, leukocyte count (differential count in case of abnormal numbers)
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- post-mortem examination on all animals dying on test or sacrificed afterward
HISTOPATHOLOGY: Yes
- 46 treated surviving animals (allocation to dose groups unclear) - Clinical signs:
- no effects observed
- Description (incidence and severity):
- Significant, but fully attributed to technical accidents (intratracheal application), not related to test substance
- Mortality:
- no mortality observed
- Description (incidence):
- Significant, but fully attributed to technical accidents (intratracheal application), not related to test substance
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Weights: steady increased steadily. No dose effect. Male weight range 200-310 g at end of treatment (EOT), 240-370 g 4 weeks later. Female weight range 160-205 g at EOT, 185-235 g 4 weeks later.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Prothrombin times normal (29.26 - 36.55 sec); coagulation times relatively high (5-7 min); erythrocytes+hemoglobin: lower normal range. Leucocytes: wide range (300-5300 in 3 animals, >10000 in 2 animals), no influence on differential count
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Hyperemic hemorrhagic lungs, seropurulent pleurisy, pericarditis in animals dying - fully attributed to accidental intratracheal administration. No significant abnormal changes in rats necropsied at EOT.
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No significant abnormal changes upon microscopical examination of internal organs at any dose.
- Histopathological findings: neoplastic:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Maximum dose administered
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
- Critical effects observed:
- not specified
- Conclusions:
- No significant changes were observed at any dose, including the maximum. Non-guideline study, not considered to be reliable.
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Mostly a review article on various toxicological and pharmacological properties of salicylamide; however, author cites an own 67-day repeated-dose experiment with mice. No experimental details, little information on clinical symptoms. No guideline followed.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Application of 250 mg salicylamide/kg bw in the drinking water for 67 days
- GLP compliance:
- no
- Limit test:
- no
- Species:
- mouse
- Strain:
- not specified
- Sex:
- not specified
- Route of administration:
- oral: drinking water
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 67 days
- Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
250 mg/kg body weight
Basis:
nominal in water - No. of animals per sex per dose:
- no data
- Control animals:
- yes, concurrent no treatment
- Dose descriptor:
- NOEL
- Effect level:
- >= 250 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- other: No observable distinction from control animals
- Critical effects observed:
- not specified
- Endpoint:
- repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Non-guideline study not performed under GLP. Non-standard study design. 3 –generations Studied in mice. Only a low level of experimental detail reported. Route of administration was in the diet at 0.1%, 0.5% or 1.0%. No data provided to show achieved concentration, homogeneity or stability in the diet preparations. Purity/composition/origin of test substance not given. Food consumption not shown but achieved doses reported as 143, 688 or 1345 mg/kg/day respectively representing 10%, 70% and 95% of the acute oral LD50. Results do not give detail of the clinical condition of the animals other than a condition percentage that was assessed on a 5 weekly basis. No record of the animal breeding procedures. Reproductive parameters are not measured in detail (44%-45% of all females across all dose groups and generations did not litter. However no dose response and no further data given) – number of females to litter (%) and pups born that were raised to weaning age (%) were reduced in all treated groups with no dose response. Parental survival time was significantly reduced compared with controls for all dose groups. As was percentage of pups raised to weaning age. A NOAEL was not derived.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Male and female mice in mated and unmated groups of five were powder-fed with 0.1, 0.5, and 1.0% of the test substance in the diet, starting at weaning in each generation. The condition of the mice was recorded at 5-week intervals. Food consumption and animal weight (weekly) were recorded for 50 weeks. Litters and survival of pups, as well as neoplasm formation and deaths (survival times) are reported as averages.
- GLP compliance:
- no
- Limit test:
- no
- Species:
- mouse
- Strain:
- other: ABC-A, albino, inbred for 25 generations
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: developed in author's laboratory, derived from ABC mice (Dr. J.J. Bittner)
- Age at study initiation: weanling
- Weight at study initiation: no data
- Fasting period before study: no
- Housing: cages of 5, mated groups: 2 males and 3 females
- Diet (ad libitum): Purina Labeena, Ralston-Purina Co., St. Louis, USA
- Water (ad libitum): tap water
- Acclimation period: none
ENVIRONMENTAL CONDITIONS
- Temperature (°C), humidity (%), air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 14 hours dark, 10 hours light - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Remarks:
- powder feeding
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): twice weekly
- Mixing appropriate amounts with (Type of food): commercial food (Purina Labeena), finely ground
- Storage temperature of food: room temperature
VEHICLE
- none - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- lifetime (averages 45.6 to 50.0 weeks in first generation) , start at weaning
- Frequency of treatment:
- continuous, daily
- Remarks:
- Doses / Concentrations:
0.1, 0.5, and 1.0% in feed
Basis:
nominal in diet - Remarks:
- Doses / Concentrations:
143, 688, and 1345 mg/kg bw/day
Basis:
other: mean uptake calculated for whole dose groups, from food intake - No. of animals per sex per dose:
- 52-54 in first generation (both sexes, no details on sex)
35-54 in second generation (both sexes, no details on sex)
9-21 in third generation (both sexes, no details on sex) - Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: 2, 10, and 20 times the expected maximal human therapeutic dosage
- Rationale for animal assignment (if not random): no data
- Rationale for selecting satellite groups: mated and unmated groups, not further specified
- Post-exposure recovery period in satellite groups: none
- Section schedule rationale (if not random): animals maintained until spontaneous death - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily (for mortality, litters)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: 5-week intervals
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for groups of animals determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
OTHER:
- number of litters born
-number of young raised to weaning age - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (no table): probably limited to observation of mammary carcinoma
HISTOPATHOLOGY: No - Statistics:
- Survival time per dose group (mean and standard error), with significant differences at p <= 0.01
Mean condition percentage for a 60-week period: average of 6 observations (at 10 week intervals), with gradings good (10), fair (5), poor (3), very poor (1), dead (0)
% of mated females having no litters
% of litters not raised to weaning
Mean number of pups born per female
Mean number of pups weaned per female
% of females developing neoplasms - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- mean survival times in first generation: significantly shortened: 60.5 weeks in control, 50.0 weeks at dose 0.1%, 46.1 weeks at dose 0.5%, 45.6 weeks at dose 1.0%. No difference in survival times between generations.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- mean survival times in first generation: significantly shortened: 60.5 weeks in control, 50.0 weeks at dose 0.1%, 46.1 weeks at dose 0.5%, 45.6 weeks at dose 1.0%. No difference in survival times between generations.
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- 0.1% diet: 143 mg/kg/day, 0.5% diet: 688 mg/kg/day, 1.0 % diet: 1345 mg/kg/day
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- no increase in % females with neoplasms
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
- condition maintenance percentage, with gradings good (10), fair (5), poor (3), very poor (1), dead (0): similar to controls after 10 weeks, 79% of controls after 20 weeks, steady decline to 29% of controls at 60 weeks (dose 1.0% of diet, first generation) - Dose descriptor:
- NOAEL
- Effect level:
- < 1 000 mg/kg diet
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Significant shortening of mean survival times
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
- Critical effects observed:
- not specified
- Conclusions:
- The study is considered to be relevant, but not reliable or suitable for risk assessment or classification and labeling purposes with regard to repeat dose toxicology.
Referenceopen allclose all
No detectable difference between treated and control animals at the end of the study (67 days).
Repeated doses of 10%, 70%, and 95% of the acute LD50 decreased the mean survival time up to 1/3 (dose-dependent); the effect was highly significant at all doses. No influence of the test substance on the incidence of mammary carcinoma was observed at any concentration.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- A number of repeated-dose toxicity studies via the oral route were conducted, but all before the introduction of relevant OECD testing guidelines. No study identified a NOAEL for repeated-dose toxicity for salicylamide and none are regarded as adequate for use in risk assessment and classification and labeling.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The 13 -week rat study of Ichniowski (1946), though not conforming to any guideline, and compromised by high accidental mortalities (intratracheal application), is nevertheless considered relevant, although not reliable. It suggests that the subchronic NOAEL of salicylamide is >200 mg/kg bw, since no adverse effects were observed in the examined parameters, including histopathology and haematology.
The 67-day mouse study (Drebinger 1952), though inadequately documented, supports this finding, since no signs of toxicity were found at 250 mg/kg.
In contrast, the combined 3-generation mouse lifetime feeding study (Wright 1967) used far higher doses (up to 1345 mg/kg bw/day), at which depression of physical condition (not further specified) and shortening of survival time were observed. A consistent interpretation and comparison is not possible.
No study identified a NOAEL for repeated-dose toxicity for salicylamide and none are regarded as adequate for use in risk assessment and classification and labelling.
Justification for selection of
repeated dose toxicity via oral route - systemic effects endpoint:
The 13 -week rat study of Ichniowski (1946), though not conforming
to any guideline, and compromised by high accidental mortalities
(intratracheal application), is nevertheless considered relevant,
although not reliable. It suggests that the subchronic NOAEL of
salicylamide is >200 mg/kg bw, since no adverse effects were observed in
the examined parameters, including histopathology and haematology.
Justification for classification or non-classification
On the basis of the available data, salicylamide does not meet the criteria for classification and labelling according to Regulation (EC) No. 1272/2008, Annex I, Part 3, 3.9. The available data are not conclusive.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
